台州博士造药狂飙,剑指200个亿

21世纪经济报道
Dec 23, 2024

记者丨韩璐  浙商俞德超控制的信达生物,狂飙突进。  12月20日,他签发公告宣布,达伯乐®(己二酸他雷替尼胶囊)新药上市申请获批,成为信达第13款商业化产品,将惠及ROS1突变的肺癌患者。  “2027年完成20款产品上市。”  董事长、CEO俞德超正火力全开,旗下组合格外丰富,从三期临床到上市获批的各类新药,超过30款。  1-9月,信达产品收入已超60亿元,增长超5成。俞已放出豪言,到...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10